Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

被引：6
|
作者：
Hotta, Katsuyuki [1 ,2 ]
Ninomiya, Kiichiro [1 ]
Ichihara, Eiki [1 ]
Kiura, Katsuyuki [1 ]
机构：
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan
来源：
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 24卷 / 01期
基金：
日本学术振兴会;
关键词：
Lung cancer; Treatment; Re-biopsy; CISPLATIN-BASED CHEMOTHERAPY; LOW-VOLUME HYDRATION; SPATIOTEMPORAL T790M HETEROGENEITY; EGFR-MUTANT; PROSPECTIVE FEASIBILITY; OPEN-LABEL; EXPRESSION; MUTATIONS; ALECTINIB; 1ST-LINE;
D O I：
10.1007/s10147-018-1344-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. Thisreview reports that the significance of a re-biopsy varies depending on the clinical situation.
引用
收藏
页码：41 / 45
页数：5
相关论文
共 50 条
  • [41] Clinical significance of vimentin-positive AXL-expressing circulating tumor cells in advanced non-small-cell lung cancer patients
    Ikeda, Mio
    Koh, Yasuhiro
    Teraoka, Shunsuke
    Sato, Koichi
    Kanai, Kuninobu
    Hayata, Atsushi
    Tokudome, Nahomi
    Akamatsu, Hiroaki
    Ozawa, Yuichi
    Akamatsu, Keiichiro
    Endo, Katsuya
    Higuchi, Masayuki
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [42] Re-biopsy patterns among non- small cell lung cancer patients(pats) in Japan: a retrospective study
    Yoshida, Tatsuya
    Satouchi, Miyako
    Kurata, Takayasu
    Nosaki, Kaname
    Seto, Takashi
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer
    Matsumoto, Tomohiro
    Hasebe, Terumitsu
    Baba, Yasutaka
    Chosa, Keigo
    Kondo, Shota
    Yamada, Shunsuke
    Yoshimatsu, Rika
    Kubota, Tetsuya
    Fujitaka, Kazunori
    Awai, Kazuo
    Yamagami, Takuji
    ANTICANCER RESEARCH, 2018, 38 (06) : 3587 - 3592
  • [44] THE SIGNIFICANCE OF HISTOLOGY IN NON-SMALL-CELL LUNG-CANCER
    ROSENTHAL, SA
    CURRAN, WJ
    CANCER TREATMENT REVIEWS, 1990, 17 (04) : 409 - 425
  • [45] Carbonyl reductase expression and its clinical significance in non-small-cell lung cancer
    Takenaka, K
    Ogawa, E
    Oyanagi, H
    Wada, H
    Tanaka, F
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (08) : 1972 - 1975
  • [46] Clinical Significance of Nodal DCsign Expression in Non-small-cell Lung Cancer Patients
    Aoki, Masaya
    Kamimura, Go
    Morizono, Shoichiro
    Tokunaga, Takuya
    Umehara, Tadashi
    Harada-Takeda, Aya
    Maeda, Koki
    Nagata, Toshiyuki
    Ueda, Kazuhiro
    Tabata, Kazuhiro
    Murakami, Gen
    Sato, Masami
    ANTICANCER RESEARCH, 2023, 43 (07) : 3003 - 3013
  • [47] Clinical significance of marrow micrometastases on outcome in operable non-small-cell lung cancer
    Hodge, Andrew J.
    Sturm, Marian
    Shaw, Kathryn
    ANZ JOURNAL OF SURGERY, 2006, 76 (08) : 765 - 765
  • [48] Clinical significance of serum miR-25 in non-small-cell lung cancer
    Li, J.
    Yu, M.
    Liu, Z.
    Liu, B.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2019, 76 (03) : 111 - 116
  • [49] Clinical significance of the tumor microenvironment in non-small cell lung cancer
    Shimizu, Katsuhiko
    Okita, Riki
    Nakata, Masao
    ANNALS OF TRANSLATIONAL MEDICINE, 2013, 1 (02)
  • [50] Quantification of serum MET in non-small-cell lung cancer and its clinical significance
    Li, Detao
    Li, Fengzeng
    Wu, Yanfeng
    Zhou, Dandan
    Chen, Hui
    CLINICAL BIOCHEMISTRY, 2015, 48 (03) : 110 - 114
12345